Engineering the Future of Cancer Care
Integrating immune intelligence, advanced delivery platforms, & AI-driven Drug development
iOncologi, Inc. is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of intractable solid tumors—beginning with glioblastoma (GBM), one of the most aggressive and deadly brain cancers. We develop next-generation immunotherapies that reprogram and mobilize the immune system to overcome the barriers that have historically limited cancer treatment, including immune suppression, tumor heterogeneity, and the blood–brain barrier.
Our integrated platform combines advanced therapeutic design, precision drug delivery systems, and cutting-edge AI foundational models to accelerate the discovery of novel targets and to generate both universal and personalized treatment formulations. These multidisciplinary capabilities enable us to design therapies that address each patient’s unique tumor biology while retaining scalability and speed to clinic.
Driven by a commitment to patients with the highest unmet medical needs, iOncologi is advancing a pipeline of proprietary therapeutic platforms, supported by strategic collaborations with global leaders in AI, drug development, and translational medicine. With an experienced team of scientists, clinicians, and industry executives, we are working to redefine what is possible in cancer care—delivering adaptable, durable, and life-changing therapies to patients who need them most.
executive leadership
Dr. edgardo rodriguez-lebron, president & ceo
Dr. edgardo rodriguez-lebron, president & ceo
Dr. edgardo rodriguez-lebron, president & ceo
Dr. Edgardo Rodriguez-Lebron is a scientist-entrepreneur with over 25 years of experience in neuroscience, gene-based medicine, and biotech leadership. As co-founder, president, and CEO of iOncologi, he has led the company’s vision to integrate deep tech, immunotherapy, and precision delivery platforms to treat intractable solid tumors. U
Dr. Edgardo Rodriguez-Lebron is a scientist-entrepreneur with over 25 years of experience in neuroscience, gene-based medicine, and biotech leadership. As co-founder, president, and CEO of iOncologi, he has led the company’s vision to integrate deep tech, immunotherapy, and precision delivery platforms to treat intractable solid tumors. Under his leadership, iOncologi has forged strategic partnerships and advanced multiple platforms toward clinical impact.
dr. duane a mitchell founder, chairman & CSO
Dr. edgardo rodriguez-lebron, president & ceo
Dr. edgardo rodriguez-lebron, president & ceo
Dr. Duane Mitchell is an internationally recognized leader in brain tumor immunotherapy and co-director of the Preston A. Wells Jr. Center for Brain Tumor Therapy at the University of Florida. As co-founder and chairman of iOncologi, he brings decades of clinical and translational expertise in developing and advancing novel treatments for
Dr. Duane Mitchell is an internationally recognized leader in brain tumor immunotherapy and co-director of the Preston A. Wells Jr. Center for Brain Tumor Therapy at the University of Florida. As co-founder and chairman of iOncologi, he brings decades of clinical and translational expertise in developing and advancing novel treatments for malignant gliomas. His visionary leadership guides iOncologi’s scientific and strategic direction toward delivering transformative therapies for patients with limited options.
Dr. Lan Hoang-Minh director operations
Dr. edgardo rodriguez-lebron, president & ceo
Dr. Lan Hoang-Minh director operations
Dr. Lan Hoang-Minh is a biomedical scientist with extensive expertise in brain tumor biology, translational research, and clinical trial operations. As Director of Operations at iOncologi, she oversees the coordination of preclinical and clinical programs, ensuring the seamless integration of scientific, regulatory, and logistical compone
Dr. Lan Hoang-Minh is a biomedical scientist with extensive expertise in brain tumor biology, translational research, and clinical trial operations. As Director of Operations at iOncologi, she oversees the coordination of preclinical and clinical programs, ensuring the seamless integration of scientific, regulatory, and logistical components. Her deep understanding of the tumor microenvironment and hands-on experience in moving therapies from bench to bedside make her a critical driver of iOncologi’s mission to deliver breakthrough treatments to patients.
board of directors
deep expertise in drug development
iOncologi’s Board of Directors brings together accomplished leaders in oncology, biotechnology, venture investment, and strategic business development. Their collective expertise spans groundbreaking scientific discovery, clinical translation, and global commercialization, ensuring the company’s vision is guided by both deep domain knowledge and strategic foresight. United by a commitment to transforming outcomes for patients with intractable cancers, the Board provides critical leadership, governance, and strategic direction to accelerate our mission.
dr. duane a mitchell founder, chairman & CSO
dr. duane a mitchell founder, chairman & CSO
dr. duane a mitchell founder, chairman & CSO
Dr. Duane Mitchell is an internationally recognized leader in brain tumor immunotherapy and co-director of the Preston A. Wells Jr. Center for Brain Tumor Therapy at the University of Florida. As co-founder and chairman of iOncologi, he brings decades of clinical and translational expertise in developing and advancing novel treatments for
Dr. Duane Mitchell is an internationally recognized leader in brain tumor immunotherapy and co-director of the Preston A. Wells Jr. Center for Brain Tumor Therapy at the University of Florida. As co-founder and chairman of iOncologi, he brings decades of clinical and translational expertise in developing and advancing novel treatments for malignant gliomas. His visionary leadership guides iOncologi’s scientific and strategic direction toward delivering transformative therapies for patients with limited options.
Dr. Peter Kash Vice-Chairman
dr. duane a mitchell founder, chairman & CSO
dr. duane a mitchell founder, chairman & CSO
Dr. Peter Kash is a seasoned biotech entrepreneur, investor, and educator with a track record of helping build and fund transformative healthcare companies. As vice chairman of iOncologi’s Board, Dr. Kash brings extensive experience in capital formation, strategic partnerships, and business development. His guidance helps ensure that iOnc
Dr. Peter Kash is a seasoned biotech entrepreneur, investor, and educator with a track record of helping build and fund transformative healthcare companies. As vice chairman of iOncologi’s Board, Dr. Kash brings extensive experience in capital formation, strategic partnerships, and business development. His guidance helps ensure that iOncologi’s innovations reach patients while delivering strong value for stakeholders.
Mr. Paolo Fundaro Director
dr. duane a mitchell founder, chairman & CSO
Dr. Mona G. Flores Director
Paolo Fundarò is a distinguished life sciences investor and executive with a history of driving the growth of pioneering biotech companies. As a member of iOncologi’s Board, he contributes strategic guidance on corporate development, financing, and international market expansion. His insights are instrumental in positioning iOncologi as a leader in innovative oncology solutions.
Dr. Mona G. Flores Director
Dr. edgardo rodriguez-lebron, president & ceo
Dr. Mona G. Flores Director
Former Global Head of Medical AI at NVIDIA, and a board-certified cardiac surgeon, Dr. Flores is a physician-executive with deep experience in global healthcare innovation, having served in leadership roles at the intersection of technology, AI, and medicine. She brings to iOncologi’s Board a unique perspective on integrating cutting-edge
Former Global Head of Medical AI at NVIDIA, and a board-certified cardiac surgeon, Dr. Flores is a physician-executive with deep experience in global healthcare innovation, having served in leadership roles at the intersection of technology, AI, and medicine. She brings to iOncologi’s Board a unique perspective on integrating cutting-edge computational approaches with clinical insight to accelerate therapeutic breakthroughs. Her expertise supports the company’s mission to develop patient-centric treatments for the most challenging cancers.
Dr. edgardo rodriguez-lebron, president & ceo
Dr. edgardo rodriguez-lebron, president & ceo
Dr. edgardo rodriguez-lebron, president & ceo
Dr. Edgardo Rodriguez-Lebron is a scientist-entrepreneur with over 25 years of experience in neuroscience, gene-based medicine, and biotech leadership. As co-founder, president, and CEO of iOncologi, he has led the company’s vision to integrate deep tech, immunotherapy, and precision delivery platforms to treat intractable solid tumors. U
Dr. Edgardo Rodriguez-Lebron is a scientist-entrepreneur with over 25 years of experience in neuroscience, gene-based medicine, and biotech leadership. As co-founder, president, and CEO of iOncologi, he has led the company’s vision to integrate deep tech, immunotherapy, and precision delivery platforms to treat intractable solid tumors. Under his leadership, iOncologi has forged strategic partnerships and advanced multiple platforms toward clinical impact.
strategic advisors
Dr. Catherine flores founder, inventor & Advisor
Dr. Catherine flores founder, inventor & Advisor
Dr. Catherine flores founder, inventor & Advisor
Dr. Catherine Flores is a pioneering scientist in hematopoietic stem cell biology and tumor immunology, recognized for her innovative work on reprogramming the tumor microenvironment to overcome immune suppression. As co-founder of iOncologi, she brings deep expertise in translating cell-based immunotherapies from bench to bedside. Her re
Dr. Catherine Flores is a pioneering scientist in hematopoietic stem cell biology and tumor immunology, recognized for her innovative work on reprogramming the tumor microenvironment to overcome immune suppression. As co-founder of iOncologi, she brings deep expertise in translating cell-based immunotherapies from bench to bedside. Her research at the University of Florida has laid the foundation for breakthrough approaches that activate and sustain anti-tumor immunity, shaping iOncologi’s mission to tackle the most intractable solid tumors.
dr. elias sayour inventor & Advisor
Dr. Catherine flores founder, inventor & Advisor
Dr. Catherine flores founder, inventor & Advisor
Dr. Elias Sayour is a leading physician-scientist in pediatric neuro-oncology and immunotherapy, renowned for pioneering vaccine-based strategies to combat aggressive brain cancers. As the inventor of one of iOncologi’s core therapeutic platforms, his groundbreaking work at the University of Florida has advanced the field of immune-modula
Dr. Elias Sayour is a leading physician-scientist in pediatric neuro-oncology and immunotherapy, renowned for pioneering vaccine-based strategies to combat aggressive brain cancers. As the inventor of one of iOncologi’s core therapeutic platforms, his groundbreaking work at the University of Florida has advanced the field of immune-modulating therapeutics. In his role as scientific advisor, Dr. Sayour guides iOncologi’s translational and clinical strategy, helping to rapidly move transformative treatments into trials for patients with few options.